Diffusion MRI in Heart Failure
Massachusetts General Hospital · NCT02973633
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–85 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Early Phase 1
- Target enrollment
- 160
- US sites recruiting
- 1
- Study start
- June 30, 2017
- Record last updated
- December 24, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The development of symptomatic heart failure is frequently preceded by a pre-clinical period of structural remodeling in the heart. The remodeling process driving this transition, however, remains poorly understood. The investigators hypothesize that imaging the diffusion of water in the heart with MRI will allow its microstructure to be resolved. The investigators further hypothesize that the characterization of microstructural changes in the heart will help elucidate the pathogenesis of heart failure and the transition from a compensated to a decompensated state. Patients with recent myocardial infarcts and left ventricular hypertrophy, who are at risk for the development of heart failure, will be enrolled. The participants will undergo serial diffusion tensor MRI (DTI) imaging of the heart to characterize changes in myocardial microstructure over time.
Being studied: Diffusion Tensor MRI (DTI); Gadolinium DOTA Meglumine
Conditions: Heart Failure; Myocardial Infarction; Left Ventricular Hypertrophy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Healthy adults with no history of hypertension, diabetes or heart disease
- Patients with ST Elevation MI within last 6-10 weeks who are angina free, and have been seen by a cardiologist since discharge
- Patients with episode of heart failure within last 12 months and left ventricular hypertrophy, documented by echocardiogram or MRI.
Exclusion Criteria
- Presence of metallic foreign bodies/objects
- Selected medical devices and implants
- Pacemakers, implantable defibrillators, life vests
- Coronary artery stent within last 6 weeks (unless the stent is a MRI-inert chromium-cobalt stent)
- Known untreated ventricular arrhythmia such as sustained ventricular tachycardia within last 12 months
- Atrial fibrillation that is not well rate controlled (heart rate >125)
- Unstable angina within last 2 months that has not been fully evaluated by a cardiologist
- Syncope within last 6 weeks
- Hemodynamic instability (Systolic BP less than 100 or greater than 180)
- Decompensated heart failure (inability to lie flat and perform a breath-hold).
- Glomerular filtration rate (GFR) \< 60 for those receiving gadolinium.
- Labile GFR that is not stable/similar on last 2 measurements (for those receiving gadolinium).
- Patients with GFR \< 20 or on any form of dialysis.
- Infiltrative cardiomyopathy (amyloid, sarcoid, hemachromatosis)
- Recent surgery (within the last 3 months)
- Prior stroke with large residual deficit
- Presence of liver or respiratory failure
- Pregnancy and nursing mothers
- Claustrophobia
- Known seizure disorder
Recruiting US locations
Massachusetts General Hospital
Charlestown, MA 02129
Study contacts (from the official record)
- David E. Sosnovik, MD · 617-724-3407 · sosnovik@nmr.mgh.harvard.edu
Similar studies in Massachusetts
All heart & blood pressure studies in Massachusetts →- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Boston, MA + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Boston, MA + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersPhase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
Massachusetts General Hospital
- Location
- Boston, MA
- Eligibility basics
- Ages 18–85